Anti-Leucine-rich repeat serine/threonine-protein kinase 2 (LRRK2) Antibody

LRRK2 is a member of the leucine-rich repeat kinase family. It role is yet unknown but it may play a role in the phoshorylation of proteins central to parkinson diseases. LRRK2 contains an ankryin repeat region, a leucine-rich repeat (LRR) domain, a kinase domain, a DFG-like motif, a RAS domain, a GTPase domain, a mLK-like domain and a WD40 domain. LRRK2 is present in the cytoplasm but also associates with the mitochondrial outer membrane. Defects in LRRK2 are the cause of Parkinson disease 8 (PARK8) . Parkinson disease is characterised by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. PARK8 is an autosomal-dominant late-onset parkinsonism, characterized by onset from 50 to 65 years, with slow progression and relatively benign course.

Our Anti-Leucine-rich repeat serine/threonine-protein kinase 2 (LRRK2) sheep polyclonal primary antibody detects human Leucine-rich repeat serine/threonine-protein kinase 2 (LRRK2), and is whole serum. It is validated for use in IHC-Frozen.

A synthetic peptide (LKRKRKILSSDDSLRSS; aa 946-962) as part of human LRRK2 protein conjugated to the Blue Carrier Protein has been used as the immunogen.

Spin vial briefly before opening. Reconstitute in 100 μL sterile-filtered, ultrapure water. Centrifuge to remove any insoluble material. After reconstitution keep aliquots at -20°C for a higher stability, and at 2-8°C with an appropriate antibacterial agent.